Physician profile
Isaac Dike
NPI 1508227844
$948.63
in general payments reported to CMS, 2019-2025
11 companies · $635 in 2025
The $635 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $29.11 · 2023: $68.20 · 2024: $217 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $294.48 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $266.92 | 2023-2025 | |
| Viatris Specialty LLC | $121.84 | 2025 | Yupelri |
| Lilly USA, LLC | $76.01 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $59.01 | 2023-2024 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $29.11 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.55 | 2024-2025 | |
| Amgen INC. | $22.44 | 2025 | Otezla, Repatha |
| Fidia Pharma USA INC. | $19.78 | 2025 | Hyalgan |
| Novo Nordisk INC | $16.59 | 2023 | Wegovy |
| Pfizer INC. | $13.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Dike listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.